Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patient completed participation in ENB-002-08 (NCT00744042)~* Written informed consent by parent or other legal guardian prior to any study procedures being performed~* Parent or other legal guardian willing to comply with study requirements~Exclusion Criteria~* History of sensitivity to any of the constituents of the study drug~* Clinically significant disease that precludes study participation~* Enrollment in any study (other than ENB-002-08) involving an investigational drug, device, or treatment for HPP (e.g., bone marrow transplantation)

- Gender: ALL
- Minimum Age: 24 Weeks
- Maximum Age: 42 Months
- Healthy Volunteers: f

Study Arms:
- asfotase alfa (Type: EXPERIMENTAL): An initial single intravenous (IV) infusion of 2 mg/kg asfotase alfa, followed by subcutaneous (SC) injections of 1 mg/kg asfotase alfa 3 times per week

Based on this trial design, predict the completion outcome and termination type (if applicable).